Amryt Pharma: Funding, Investors & Team (Sep 2026)
Amryt Pharma is a specialty pharmaceutical company focused on the developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt’s lead product, Episalvan, received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016. Amryt intends to further develop Episalvan as a new treatment for a hereditary skin disorder called Epidermolysis Bullosa in both Europe and the U.S. Amryt’s earlier stage products are focussed on developing novel, next generation somatostatin analogue (“SSA”) peptide medicines for patients with rare neuroendocrine diseases, where there is high unmet medical needs. These include acromegaly and Cushing's disease.
Amryt Pharma has raised $125M across 1 funding round on record, the most recent a Post-IPO Debt of $125M announced in Feb 2022.
That round is above the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
Amryt Pharma Company Profile and Key Stats
Latest funding round on record: Feb 2022.
Amryt Pharma Funding Rounds
Amryt Pharma Founders and Leadership Team
No contact details are on record for this team yet.
Amryt Pharma Funding Compared to Other Health Care Startups
Amryt Pharma's latest round of $125M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Amryt Pharma in Health Care and Dublin
Companies Similar to Amryt Pharma
NeuroBell are developing a novel medical device providing portable EEG monitoring with real-time &automated…
Vertigenius designs and deploys customized exercises using an easy-to-use clinician portal and even uses a…
CrannMed aims to eliminate chronic pain, restore mobility, and stop disease progression for patients with…
Neurent Medical is a medical device startup that develops non-surgical treatments for inflammatory sino-nasal…
It has been estimated that up to 25% of people with diabetes will develop a foot ulcer at some point in their…
Rockfield Medical Devices is an innovative SME in the area of human centered design process in the medical…
The Tight Alright technology developed by FeelTect is a connected-health device designed to measure and…
ProVerum Medical is a healthcare company that creates new therapies for benign prostatic hyperplasia (BPH).…
CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with…
When a patient is critically ill, giving their doctor the right information at the right time can mean the…
SISU is a collection of doctor-led, patient-centric aesthetic medical clinics.
Vida Care offers patients the opportunity to easily schedule various routine tests such as blood,…
Amryt Pharma Funding FAQs
What does Amryt Pharma do?
Amryt Pharma is a specialty pharmaceutical company focused on the developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt’s lead product, Episalvan, received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016. Amryt intends to further develop Episalvan as a new treatment for a hereditary skin disorder called Epidermolysis Bullosa in both Europe and the U.S. Amryt’s earlier stage products are focussed on developing novel, next generation somatostatin analogue (“SSA”) peptide medicines for patients with rare neuroendocrine diseases, where there is high unmet medical needs. These include acromegaly and Cushing's disease.
How much funding has Amryt Pharma raised?
Amryt Pharma has raised $125M across 1 round on record. The most recent is a Post-IPO Debt of $125M announced in Feb 2022.
When did Amryt Pharma last raise funding?
Amryt Pharma's most recent funding round on record is a Post-IPO Debt of $125M, announced in Feb 2022.
Who is the CEO of Amryt Pharma?
Joseph Wiley is listed as CEO at Amryt Pharma.
Where is Amryt Pharma headquartered?
Amryt Pharma is based in Dublin, Ireland.
How many employees does Amryt Pharma have?
Amryt Pharma is in the 51-100 employee band.
How does Amryt Pharma's funding compare to other Health Care startups?
Amryt Pharma's latest round of $125M is above the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's Amryt Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Amryt Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.